Use of aspirin to reduce risk of initial cardiovascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomized, double-blind, placebo-controlled trial - Gaziano, JM; Brotons, C; Coppolecchia, R (Lancet, 2018)